Biotech | September 08, 2021
Biocon settles suit with Celgene for generic Revlimid
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained
ABB Drives play a key role in the cleanroom infrastructure of Bharat Biotech, India’s first indigenous Covid-19 vaccine manufacturer. The drives are easy to commission, use and ensure higher energy efficiency
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
Subscribe To Our Newsletter & Stay Updated
